[ CAS No. 372118-67-7 ] {[proInfo.proName]}

Name: 372118-67-7|Pyrimidin-2-ylmethanamine hydrochloride|98%
Brand: Ambeed
SKU: A117604
Price: 8.0 USD
Availability: InStock
Rating: 97 (28 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 372118-67-7 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 372118-67-7 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 372118-67-7 ]

SDS Specification

Alternatived Products of [ 372118-67-7 ]

Product Details of [ 372118-67-7 ]

CAS No. :	372118-67-7	MDL No. :	MFCD08062208
Formula :	C₅H₈ClN₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	RZNKMZKAXJTLQR-UHFFFAOYSA-N
M.W :	145.59	Pubchem ID :	17848325
Synonyms :

Calculated chemistry of [ 372118-67-7 ]

Physicochemical Properties

Num. heavy atoms :	9
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.2
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	36.67
TPSA :	51.8 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.26 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	-0.1
Log Po/w (WLOGP) :	0.59
Log Po/w (MLOGP) :	-0.61
Log Po/w (SILICOS-IT) :	0.55
Consensus Log Po/w :	0.09

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.11
Solubility :	11.4 mg/ml ; 0.0782 mol/l
Class :	Very soluble
Log S (Ali) :	-0.54
Solubility :	42.5 mg/ml ; 0.292 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.63
Solubility :	3.38 mg/ml ; 0.0232 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.33

Safety of [ 372118-67-7 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 372118-67-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 372118-67-7 ]

[ 372118-67-7 ] Synthesis Path-Downstream 1~30

1
[ 448920-98-7 ]
[ 372118-67-7 ]
C₁₈H₁₉ClF₂N₄O [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 5024 - 5033

2
[ 372118-67-7 ]
[ 104326-73-0 ]
[ 870517-13-8 ]

Reference： [1]Patent: WO2005/113553,2005,A2 .Location in patent: Page/Page column 88-89

3
[ 14080-23-0 ]
[ 372118-67-7 ]

Yield	Reaction Conditions	Operation in experiment
44%	With hydrogenchloride; palladium 10% on activated carbon; hydrogen; In methanol; water; at 20℃; for 3h;	To a stirring solution of pyrimidine-2-carbonitrile (2.0 g, 19.0 mmol) in methanol (50 mL) were added 10% Pd/C (300 mg), 12 N HCl (1.5 mL) under 2 atmosphere. The reaction mixture was stirred under atmosphere (balloon pressure) at RT for 3 h. After consumption of the starting material (by TLC), the reaction mixture was filtered through a pad of celite and the pad was washed with methanol. Obtained filtrate was concentrated under reduced pressure to afford crude compound which was triturated with diethyl ether to obtained compound 4S-AP (1.2 g, 44%) as white solid. 1H-NMR: (500 MHz, DMSO-d6): delta 8.87 (d, J = 5.0 Hz, 2H), 8.69 (br s, 2H), 7.52 (t, J = 5.0 Hz, 1H), 4.24 (s, 2H). Mass (ESI) (m/z): 110.3 [M++1].
22 g		Raney nickel (18 g) was added to a mixture of 2-cyanopyrimidine (30 g) and 2- butanol (150 ml) in an autoclave and applied 4-5 kg/cm2 hydrogen pressure. The reaction mixture was heated to 75-80C and stirred for 15 hours. Cooled the reaction mixture to 25- 30C and hydrogen gas pressure was released. Filtered the reaction mixture through hyflo bed and washed with 2-butanol. Carbon (1.5 g) was added to the filtrate at 25-30c and stirred for 15 minutes. Filtered the reaction mixture through hyflo bed and washed with 2- butanol. Adjusted the pH of the reaction mixture to 3 with 2-butanolic hydrochloride at 25- 30C and stirred for 1 hour. Filtered the solid and washed with 2-butanol. Methanol (60 ml) was added to the obtained solid, heated the reaction mixture 65-70C and stirred for 15 minutes. Cooled the reaction mixture to 25-30C, ethyl acetate (90 ml) was added to it and stirred for 1 1/2 hour at 25-30C. Filtered the precipitated solid, washed with ethyl acetate and then dried to get title compound.Yield: 22 g; Decomposition: 207-213C; Purity by HPLC: 99.1%.

Reference： [1]Patent: WO2014/120786,2014,A1 .Location in patent: Paragraph 0139
[2]Patent: WO2015/1567,2015,A1 .Location in patent: Page/Page column 22; 23
[3]Patent: WO2005/113553,2005,A2 .Location in patent: Page/Page column 88-89

Yield	Reaction Conditions	Operation in experiment
		(2) 2-Aminomethylpyrimidine maleate 70 g and ethanol 280 ml are put in a 4 neck-flask (2 L). To the suspension is dropped a solution of hydrogen chloride in ethanol (previously prepared) 69.6 g over a period of 10 minutes, and the mixture is stirred at 70 C. for 2 hours. After reaction ethyl acetate 560 ml is dropped thereto at 60 C. and the mixture is gradually cooled to 30 C. and stirred for 30 minutes under ice cooling. The resulting crystals are collected by filtration, washed with a cold mixture of ethanol and ethyl acetate (1:2) 140 ml and dried to give 2-aminomethylpyrimidine hydrochloride as powder-like crystals 43.1 g. mp 207-210 (decomposition)

5
[ 372118-67-7 ]
[ 4755-77-5 ]
ethyl 2-oxo-2-[(pyrimidin-2-yl)methylamino]acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 0.25h;	To a solution <strong>[372118-67-7]2-aminomethylpyrimidine hydrochloride</strong> (0.96 g, 6.6 mmol) in dichloromethane (15 mL) was added DIEA (2.8 mL, 16.0 mmol). The mixture was cooled to 0 C. and ethyl oxalyl chloride (0.81 mL, 7.3 mmol) was added. After 15 min, the solvent was removed under reduced pressure and the residue was purified by pressurized silica gel column chromatography using a gradient of 0-5% MeOH in dichloromethane. The solvent was removed under reduced pressure from the fractions containing product to give the title compound as an oil. 1H NMR (400 MHz, DMSO-d6) delta 9.34 (br t, 1H), 8.77 (d, J=5.0 Hz, 2H), 7.41 (t, J=5.0 Hz, 1H), 4.54 (d, J=6 Hz, 2H), 4.28 (q, J=7 Hz, 2H), 1.29 (t, J=7 Hz, 3H); HPLC RT=1.67 min (Method A); ES MS M+1=210.

Reference： [1]Patent: US2008/139579,2008,A1 .Location in patent: Page/Page column 25

6
[ 372118-67-7 ]
[ 1426383-90-5 ]
[ 1426383-98-3 ]

Yield	Reaction Conditions	Operation in experiment
72%		To a solution of 2-((6,8-dichloro-3-(methoxycarbonyl)naphthalen-1 - yl)(methyl)annino)acetic acid (60 mg, 0.18 mmol) in DMF (1 ml_) is added CDI (40 mg, 0.25 mmol), and the mixture is heated at 50 C for 30 min. Then pyrimidin-2- ylmethanamine hydrochloride (36 mg, 0.25 mmol) and DIPEA (34 mg, 0.26 mmol) are added, and the reaction mixture is stirred at 50 C for 3 days (LC-MS control). The mixture is allowed to cool to rt, diluted with water (5 mL) and brine (6 mL), and extracted with EtOAc (4x). The organic extracts are combined, dried over Na2SO4, filtered and evaporated. The residue is purified by flash chromatography on silica (eluent - EtOAc:hexane or DCM:MeOH) to give the title compound in 72% yield as a yellow oil.

Reference： [1]Patent: WO2013/30358,2013,A1 .Location in patent: Paragraph 00213

7
[ 372118-67-7 ]
[ 1569298-31-2 ]
[ 1569298-32-3 ]

Yield	Reaction Conditions	Operation in experiment
305 mg	With triethylamine; In tetrahydrofuran; at 20℃; for 4h;	510 mg (80%, 0.93 mmol) of <strong>[372118-67-7]2-aminomethylpyrimidine hydrochloride</strong> was mixed with 3 mL THF and 290 muL (2.07 mmol) triethylamine were added. After 5 min, intermediate 77 mixed with 7 mL THF was added, and the mixture was stirred at ambient temperature for 2 h. 290 muL (2.07 mmol) triethylamine were added and the mixture was stirred for an additional 2 h. The mixture was evaporated and the residue purified by MPLC (25 g silica, cyclohexanes/ethyl acetate (110/0 to 70/30 in 50 min). Fractions containing the product were combined and the solvent was evaporated to yield 305 mg of intermediate 78.LC-MS (method 2): tR=1.00 min. m/z 501/3 Br (M+H+)1HNMR (DMSO-d6) corresponds with the desired product.

Reference： [1]Patent: US2014/57927,2014,A1 .Location in patent: Paragraph 0372-0374

8
[ 372118-67-7 ]
[ 1621435-12-8 ]
[ 1621482-78-7 ]

Yield	Reaction Conditions	Operation in experiment
36.5%	With ammonium chloride; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0 - 20℃; for 12h;	To a stirring solution of compound 4S-W (5 g, 20.4 mmol) in CH2Cl2 (50 mL) were added DIPEA (11 mL, 61.2 mmol), EDCI (5.84 g, 30.6 mmol), HOBT (4.68 g, 30.6 mmol), 4S-AP (3.52 g, 24.4 mmol) at 0 C and stirred to RT for 12 h. After consumption of the starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with CH2Cl2 (2 x 100 mL). The combined organic layer was washed with citric acid (1 x 100 mL) followed by bicarbonate solution (1 x 100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Obtained crude material was purified by silica gel column chromatography eluting with 2% MeOH/DCM to afford compound 4S-14 (2.5 g, 36.5%) as an off-white solid. 1H-NMR: (400 MHz, DMSO-d6): delta 8.75 (d, J= 4.8 Hz, 2H), 8.23 (d, J= 5.2 Hz, 1H), 7.38 (t, J = 5.2 Hz, 1H), 5.16 (t, J = 5.2 Hz, 1H), 4.53-4.41 (m, 2H), 3.92-3.82 (m, 2H), 3.67-3.63 (m, 1H), 3.54-3.48 (m, 1H), 2.32-2.19 (m, 2H), 2.15-1.97 (m, 2H), 1.39 (s, 9H). Mass (ESI): m/z 337.4 [M++1].

Reference： [1]Patent: WO2014/120786,2014,A1 .Location in patent: Paragraph 0165

9
[ 372118-67-7 ]
[ 330785-84-7 ]
[ 330784-47-9 ]

Yield	Reaction Conditions	Operation in experiment
145 g	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 0 - 5℃; for 14h;	Hydroxybenzotriazole (51.6 g) followed by (S)-4-(3-chloro-4-methoxybenzylamino)- 2-(2-(hydroxymethyl)pyrrolidin-l-yl) pyrimidine-5-carboxylic acid (150 g) and l -ethyl-3-(3- dimethylamino propyl)carbodiimide hydrochloride (128.1 g) were added to a pre-cooled mixture of <strong>[372118-67-7]pyrimidin-2-ylmethanamine hydrochloride</strong> compound of formula- 12a (72.3 g), triethylamine (77.3 g) and dimethylformamide (750 ml) at 0-5C and stirred for 14 hours at 0-5C. Quenched the reaction mixture with 5% aqueous potassium carbonate solution (3.75 lit) at a temperature below 30C and stirred for 3 hours at 25-30C. Filtered the solid and washed with water. Water followed by dichloromethane were added to the obtained solid and separated the organic and aqueous layers. Carbon (7.5 g) was added to the organic layer. Filtered the reaction mixture, washed with dichloromethane and distilled off the solvent completely from the filtrate and co-distilled with methanol. Cooled the obtained compound to 30-35C and methanol (1500 ml) was added to it. Heated the reaction mixture to 65-70C and stirred for 10 minutes. Cooled the reaction mixture to 25-30C and stirred for 1 hour. Filtered the solid, washed with methanol and then dried to get title compound. Yield: 145 g; Melting range: 158-163C; Purity by HPLC: 99.6%; Particle Size Distribution: D(0.1): 5.501 muiotaeta; D(0.5): 20.469 um; D(0.9): 52.006 um; D(4,3): 25.457 muetaiota.PXRD pattern of the obtained compound is represented in figure- 1 and DSC thermogram of the obtained compound is represented in figure-2.

Reference： [1]Patent: WO2015/1567,2015,A1 .Location in patent: Page/Page column 29

10
[ 372118-67-7 ]
[ 330785-84-7 ]
C₄₁H₄₅Cl₂N₁₁O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
40 g	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In ethyl acetate; at 50 - 55℃; for 6h;	A mixture of l -Ethyl-3-(3-dimethylaminopropyl)carbodiimide (48.8 g), Hydroxy benzotriazole (17.1 g), <strong>[372118-67-7]pyrimidin-2-ylmethanamine hydrochloride</strong> (12.9 g) and triethylamine (25.75 g) was added to a mixture of (S)-4-(3-chloro-4-methoxybenzylamino)-2-(2-(hydroxy methyl)pyrrolidin-l-yl) pyrimidine-5-carboxylic acid compound of formula-l 1 (50 g) and ethyl acetate (500 ml) at 25-30C. Heated the reaction mixture to 50-55C and stirred for 6 hours. Cooled the reaction mixture to 25-30C and water followed by ethyl acetate were added to the reaction mixture. Separated the organic and aqueous layers and washed the organic layer with water. Distilled off the solvent from the organic layer and then co-distilled with methanol. Methanol (150 ml) was added to the reaction mixture at 25-30C and stirred for 45 minutes. The solvent was decanted from the reaction mixture and water (500 ml) was added to the reaction mixture and stirred for 5 hours. Filtered the precipitated solid, washed with water and then dried to get the title compound. The obtained compound was further purified by preparative HPLC to get pure title compound. Yield: 40 g; Purity by HPLC: 96%. NMR (CHC13, 300 MHz) delta 1.62-2.16 (m, 9H), 3.48-3.77 (m, 6H), 3.82-3.87 (d, 7H), 4.77- 4.78 (d, 2H), 4.24-4.27 (d, 2H), 4.43-4.45 (d, 2H), 4.57-4.59 (d, 4H), 4.78-4.79 (d, 2H), 6.79- 6.87 (d, 2H), 7.15-7.18 (d, 2H), 7.26-7.46 (m, 4H), 8.43 (s, 1H), 8.49 (s, 1 H), 8.71-8.72 (d, 2H), 9.0-9.04 (t, 1 H). EIMS (M+l) m/z = 858.3. FTIR: v 3339.55, 1678.41 cm'1.

Reference： [1]Patent: WO2015/1567,2015,A1 .Location in patent: Page/Page column 31; 32

11
[ 372118-67-7 ]
2,4-bis(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxylic acid [ No CAS ]
C₂₆H₂₅Cl₂N₇O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
12.0 g	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 55 - 60℃; for 5h;	A mixture of 2,4-bis(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxylic acid compound of formula- 14 (25 g) and dimethylformamide (500 ml) was stirred for 15 minutes at 25-30C. Hydroxybenzotriazole (7.3 g) followed by l-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (18.14 g), pyrimidin-2-yl methanamine hydrochloride (10.24 g) and triethylamine (10.94 g) were added to the reaction mixture at 25-30C. Heated the reaction mixture to 55-60C and stirred for 5 hours. Cooled the reaction mixture to 25-30C, quenched the reaction mixture with 5% aqueous potassium carbonate and then stirred for 3 hours. Filtered the solid, washed with water. Dichloromethane (50 ml) was added to the obtained solid. Carbon (5 g) was added to it and stirred for 15 minutes. Filtered the reaction mixture, washed with dichloromethane and distilled off the solvent from the filtrate. Methanol (250 ml) was added to the reaction mixture at 30-35C, heated the reaction mixture to 60-65C and stirred for 10 minutes. Cooled the reaction mixture to 25-30C and stirred for 1 hour. Filtered the precipitated solid, washed with methanol and then dried to get title compound. Yield: 12.0 g; NMR (CDC13, 300 MHz) delta 3.86-3.87 (s, 6H), 4.51-4.55 (d, 4H), 4.78-4.80 (d, 2H), 6.81 (s, 2H), 7.09 (s, 2H), 7.22-7.3 (m, 5H), 8.32 (s, 1H), 8.72-8.73 (d, 2H), 9.12 (s, 1 H). EIMS (M+l )) m/z = 554.2. FTIR: v 3325.22, 1639.9 cm"1.

Reference： [1]Patent: WO2015/1567,2015,A1 .Location in patent: Page/Page column 33

12
[ 372118-67-7 ]
2-(2-bromo-6-chlorophenyl)-2-oxoacetic acid [ No CAS ]
2-(2-bromo-6-chlorophenyl)-2-oxo-N-(pyrimidin-2-ylmethyl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%		To 2-(2-bromo-6-chloro-phenyl)-2-oxo-acetic acid (37, 3.8 g, 14.42 mmol) in DCM (100 mL) was added oxalyl chloride (3.5 g, 27.57 mmol) and DMF (1 drop) at 25 C, the reaction was stirred at room temperature for 2 h, and the resulting mixture was concentrated under reduced pressure. To the residue in DCM (100 mL) was added <strong>[372118-67-7]pyrimidin-2-ylmethanamine hydrochloride</strong> (2.0 g, 13.74 mmol), stirred for 2 h, concentrated, and purified by silica-gel column chromatography eluting with EA/DCM (1:10) to afford the target compound as a yellow solid (3.4 g, 70%). LCMS (ESI): m/z = 355.9 [M+H]+

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 2907 - 2912

13
[ 372118-67-7 ]
[ 1761-61-1 ]
C₁₂H₁₂BrN₃O [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		5-bromosalicylaldehyde (2.49 mmol) and 2-aminomethylpyrimidine HCl (3.73 mmol) were combined in THF:MeOH (20:2 mL) mixture followed by addition of N,N-diisopropylethylamine (5-7 mmol). The mixture was stirred under N2 at RT for several hours. After the reaction was complete or substantially complete, 1 equiv. of NaBH4 was added and the mixture was stirred at room temperature overnight. The excess hydride was quenched with 1N HCl. The mixture was concentrated to remove most of organic solvents. Water was added and the organic phase was extracted with DCM. The organic phase was concentrated to give A.

Reference： [1]Patent: US2015/175595,2015,A1 .Location in patent: Paragraph 0508; 0510

14
[ 372118-67-7 ]
(S)-5-(1-((tert-butoxycarbonyl)amino)ethyl)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-1,3-oxazole-4-carboxylic acid [ No CAS ]
(S)-tert-butyl (1-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-4-((pyrimidin-2-ylmethyl)carbamoyl)oxazol-5-yl)ethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
73%	With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0 - 20℃; for 17h;	Step 1: (S) -tert-Butyl (1- (2- (3- (cyclopropylmethoxy) -4- (difluoromethoxy) phenyl) -4- ( (pyrimidin-2-ylmethyl) carbamoyl) oxazol-5-yl) ethyl) carbamate[2051](S) -5- (1- ( (tert-Butoxycarbonyl) amino) ethyl) -2- (3- (cyclopropylmethoxy) -4- (difluoromethoxy) phenyl) oxazole-4-carboxylic acid (250 mg, 0.53 mmol) , 2- (aminomethyl) pyrimidine hydrochloride (93 mg, 0.64 mmol) , 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (153 mg, 0.80 mmol) and 1-hydroxy-7-azabenzotriazole (182 mg, 1.33 mmol) were dissolved in 15 mL of dichloromethane. To the mixture was added N, N-diisopropylethylamine (0.37 mL, 2.14 mmol) dropwise at 0 . The resulting mixture was stirred at rt for 17 hours. The reaction mixture was washed with water (10 mL × 2) and the organic layer was dried over anhydrous sodium sulfate. The organic solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc (v/v) 1/1) to give a white solid (225 mg, 73) .[2052]1H NMR (400 MHz, CDCl3) : delta ppm 8.77 (d, J 4.9 Hz, 2H) , 8.24 (br. s, 1H) , 7.64 (dd, J18.3 Hz, J2 1.9 Hz, 1H) , 7.59 (d, J 1.7 Hz, 1H) , 7.25 -7.24 (m, 1H) , 6.71 (t, JF-H 75.0 Hz, 1H) , 5.32 -5.28 (m, 1H) , 4.91 (d, J 5.2 Hz, 2H) , 3.99 (d, J 6.9 Hz, 2H) , 1.54 (d, J 7.0 Hz, 3H) , 1.43 (s, 9H) , 1.36 -1.31 (m, 1H) , 0.72 -0.67 (m, 2H) , 0.43 -0.39 (m, 2H) and MS-ESI: m/z 560.8 [M+H]+.

Reference： [1]Patent: WO2015/161830,2015,A1 .Location in patent: Paragraph 00719

15
[ 372118-67-7 ]
[ 199915-38-3 ]
C₂₁H₁₈N₄O₂S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
98%	With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 25℃;Inert atmosphere;	A mixture of methyl amino pyrimidine (250 mg, 1 eq, 1.718 mmol), FMOC-NCS (531 mg, 1.1 eq, 1.9 mmol) and diisopropyl ethyl amine (0.3 ml, 1 eq, 1,718 mmol) was stirred in 1,4-dioxane (10 ml) at 25 oC overnight under argon atmosphere. A solid separated out from mixture was filtered and washed with water and ethyl acetate, and dried under high vaccuum. Yield 658 mg, 98%.
98%	With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 25℃;Inert atmosphere;	A mixture of methyl amino pyrimidine (250 mg, 1 eq, 1.718 mmol), FMOC-NCS (531 mg, 1.1 eq, 1.9 mmol) and diisopropyl ethyl amine (0.3 ml, 1 eq, 1,718 mmol) was stirred in 1,4-dioxane (10 ml) at 25 C overnight under argon atmosphere. A solid separated out from mixture was filtered and washed with water and ethyl acetate, and dried under high vaccuum. Yield 658 mg, 98%. Solid obtained from the reaction (658 mg, 1 eq, 1.2 mmol) was stirred in piperidine (3 ml) and dichloromethane (15 ml) at 25 C overnight. A solid percipitate was collected by filtration and washed with dichloromethane and water to give a white solid. Yield 289 mg, 98%.LCMS, 169 (MH+).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5819 - 5824
[2]Patent: WO2018/13508,2018,A1 .Location in patent: Paragraph 0163

16
[ 500860-54-8 ]
[ 372118-67-7 ]
6-chloro-N₄,N₈-dimethyl-N₂-pyrimidin-2-ylmethylpyrimido[5,4-d]pyrimidine-2,4,8-triamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
79%	With N-ethyl-N,N-diisopropylamine; In butan-1-ol; at 90℃; for 72h;	A mixture of 2,6-dichloro-N,N? -dimethyl-pynmido [5 ,4-dj pyrimidine-4,8- diamine (88) (259 mg, 1.00 mmol), pynmidin-2-ylmethanamine hydrochloride (218 mg, 1.50 mmol) and N,N-diisopropylethylamine (435 .iL, 2.50 mmol) in n-butanol (3 mL) was heated at 90C for 72 h. The reaction mixture was cooled, the precipitate were filtered, washed with water (2 x 10 mL) and dried over P205 to afford 6-chloro-N4,N8-dimethyl-N2-pyrimidin-2-ylmethyl-pyrimido[5,4-djpyrimidine-2,4,8-triamine (108) (260 mg, 79% yield).

Reference： [1]Patent: WO2017/3822,2017,A1 .Location in patent: Page/Page column 152

17
[ 372118-67-7 ]
7-[3-(3,5-dichlorophenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]indane-4-carboxylic acid [ No CAS ]
7-[3-(3,5-dichlorophenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]-N-(pyrimidin-2-ylmethyl)indane-4-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate; In dichloromethane; at 20 - 25℃;Inert atmosphere;	A solution of compound XIV.5 (1.0 eq), pyrimidin-2-ylmethanammoniumchloride (1 .2 eq), Py- BrOP (1.2 eq) in DCM (10 mL) was produced. Diisopropylethylamine (3-4 eq) was added to the mixture at 20 to 25 C. The mixture was stirred under nitrogen for several hours. The mixture was extracted with water, and the organic phase was reduced in vacuo. Compound XIV.6 was isolated from the residue via silica column chromatography.

Reference： [1]Patent: WO2017/12938,2017,A1 .Location in patent: Page/Page column 67

18
[ 372118-67-7 ]
7-[3-(3,5-dichloro-4-fluoro-phenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]indane-4-carboxylic acid [ No CAS ]
7-[3-(3,5-dichloro-4-fluorophenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]-N-(pyrimidin-2-ylmethyl)indane-4-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate; In dichloromethane; at 20 - 25℃;Inert atmosphere;	Compound 7-[3-(3,5-dichloro-4-fluoro-phenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]indane- 4-carboxylic acid was produced in analogy to examples 14 to 17. A solution of 7-[3-(3,5- dichloro-4-fluoro-phenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-5-yl]indane-4-carboxylic acid (2.5 g), pyrimidin-2-ylmethanammoniumchloride (0.95 g), PyBrOP (3.04 g) in DCM (100 mL) was produced. Diisopropylethylamine (2.25 g) was added to the mixture at 20 to 25 C. The mixture was stirred under nitrogen for several hours. The mixture was extracted with water, and the organic phase was reduced in vacuo. Compound XIV.7 was isolated from the residue via silica column chromatography.

Reference： [1]Patent: WO2017/12938,2017,A1 .Location in patent: Page/Page column 67

19
[ 372118-67-7 ]
7-[2-(3,5-dichlorophenyl)-2-(trifluoromethyl)-3H-thiophen-4-yl]indane-4-carboxylic acid [ No CAS ]
7-[2-(3,5-dichlorophenyl)-2-(trifluoromethyl)-3H-thiophen-4-yl]-N-(pyrimidin-2-ylmethyl)indane-4-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate; In dichloromethane; at 20 - 25℃;Inert atmosphere;	General procedure: A solution comprising compound XIV.9 of example 22 (1.0 eq), PyBrOP (1.2 eq), DCM (10 mL), and an ammonium chloride compound selected from pyrimidin-2-ylmethanammonium chloride, 2-pyridylmethanammonium chloride, 2-ammonium-N-(2,2,2-trifluoroethyl)acetamide chlo- ride, or 1 ,1 -dioxothietan-3-ammonium chloride (1.2 eq) was produced. Diisopropylethylamine (3-4 eq) was added to the mixture at 20 to 25 C. The mixture was stirred under nitrogen for several hours. The mixture was extracted with water, and the organic phase was reduced in vacuo. Depending on the ammonium chloride compound used, a compound XIV.10 to XIV.13 was isolated from the residue via silica column chromatography.

Reference： [1]Patent: WO2017/12938,2017,A1 .Location in patent: Page/Page column 68

20
2-aminomethylpyrimidine methanesulfonate [ No CAS ]
[ 372118-67-7 ]

Yield	Reaction Conditions	Operation in experiment
89%		The reaction flask was charged with 2-aminomethylpyrimidine methanesulfonate, cooled to -10 C,Add sodium methoxide in batches of solid, stirring 1h, filter, the filtrate back into the reaction bottle,Cooling to -10 , access to a sufficient amount of hydrochloric acid gas, reaction 2h, suction filtration, drying,To give 2-aminomethylpyrimidine hydrochloride, purity greater than 99.5%, yield 89%.

Reference： [1]Patent: CN105924402,2016,A .Location in patent: Paragraph 0013; 0014; 0015; 0016; 0017; 0018; 0019; 0020

21
[ 372118-67-7 ]
(R)-tert-butyl 4-(6-chloro-2-(chloromethyl)-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)-2-methylpiperazine-1-carboxylate [ No CAS ]
(R)-tert-butyl 4-(2-(((pyrimidin-2-yl)methylamino)methyl)-6-chloro-8-fluoro-7-(2-fluoro-6-methoxyphenyl)quinazolin-4-yl)-2-methylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
41%	With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 120℃; for 16h;	A mixture of (R)-tert-butyl 4-(6-chloro-2-(chloromethyl)-8-fluoro-7-(2- fluoro-6-methoxyphenyl)quinazolin-4-yl)-2-methylpiperazine- 1 -carboxylate (500 mg, 0.90 mmol) and <strong>[372118-67-7](pyrimidin-2-yl)methanamine hydrochloride</strong> (264 mg, 1.81 mmol) in propan-2-ol was added DIEA (948 mg, 2.71 mmol) and the resulting mixture wasstirred at 120 C for 16 h. The mixture was concentrated in vacuo, and extracted with DCM. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (5% to 10% MeOH / DCM) to afford the desired product (230 mg, 41 % yield) as a solid. ESI-MS m/z: 626.5 [M+H]

Reference： [1]Patent: WO2017/87528,2017,A1 .Location in patent: Page/Page column 197; 198

22
[ 372118-67-7 ]
[ 407-25-0 ]
C₇H₆F₃N₃O [ No CAS ]

Reference： [1]Organic Letters,2017,vol. 19,p. 6578 - 6581

23
[ 372118-67-7 ]
[ 401-67-2 ]
C₇H₇F₂N₃O [ No CAS ]

Reference： [1]Organic Letters,2017,vol. 19,p. 6578 - 6581

24
[ 372118-67-7 ]
[ 330786-34-0 ]
4-((3-chloro-4-methoxybenzyl)amino)-2-(methylthio)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-formamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%		Tosyl chloride (254 mg, 1.33 mmol), K2CO3 (538 mg, 3.9 mmol) and compound 21 (500 mg, 1.33 mmol) were added to acetonitrile (10 mL) and stirred at room temperature overnight. Compound 23 (194 mg, 1.33 mmol) was added to the prepared mixed anhydride solution, stirred at room temperature for 20 minutes, and then detected by TLC. The reaction of the starting material was completed. The mixture was diluted with water and washed with ethyl acetate. The aqueous phase was extracted twice more with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to give compound 24 (601 mg, 95% yield).
1.1 g		The product VII obtained in step (2) (1.0 g) was added to 15 ml of N, N-dimethylformamide, cooled with ice water bath under nitrogen, and HATU (1.67g) was added to the reaction mixture, triethylamine (1.3ml) was added dropwise to the reaction mixture, stirred for 10min, <strong>[372118-67-7]2-aminomethylpyrimidine hydrochloride</strong> (471mg), slowly warmed to 20 ~ 30 C and stirred for 3 ~ 18h. 48 ml of water was added to the reaction solution, the solution became turbid, and a solid precipitated. The solution was extracted with ethyl acetate twice (25 ml × 2). The organic phases were combined, the organic phase was washed twice with 30 ml of 5% sodium carbonate solution, once with 30 ml of water, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1.1 g of a white solid.

Reference： [1]Patent: CN104710411,2017,B .Location in patent: Paragraph 0025; 0075; 0076; 0077; 0078; 0079; 0080-0082
[2]Patent: CN104059025,2017,B .Location in patent: Paragraph 0042; 0043-0045; 0059-0061; 0075-0077; 0091-0093

25
[ 372118-67-7 ]
C₁₃H₁₁Cl₂N₃O₃ [ No CAS ]
2-chloro-4-((3-chloro-4-methoxybenzyl)amino)-N-[pyrimidin-2ylmethyl]pyrimidine-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93%		Tosyl chloride (254 mg, 1.33 mmol), K2CO3 (538 mg, 3.9 mmol) and 22 (436 mg, 1.33 mmol) were added to acetonitrile (10 mL) and stirred at room temperature overnight. Compound 23 (194 mg, 1.33 mmol) was added to the prepared mixed solution of the mixed anhydride, and the mixture was stirred at room temperature for 20 minutes. After completion of the reaction by TLC, the starting material was reacted. The mixture was diluted with water and washed with ethyl acetate. The aqueous phase was extracted twice more with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to give compound 25 (588 mg, yield 93%)

Reference： [1]Patent: CN104710411,2017,B .Location in patent: Paragraph 0038; 0083; 0084; 0085; 0086; 0087; 0088; 0089

26
[ 1260843-26-2 ]
[ 372118-67-7 ]

Yield	Reaction Conditions	Operation in experiment
5.3 g	With hydrogenchloride; In water;	Hydrogenation bottle was added 100mL (20vol) of ethyl acetate,50 mL water (10 vol) (purified water),2.28 g sodium hydroxide (0.0571 mol, 1.2 eq),10.9 g BoC2O anhydride (0.05 mol, 1.05 eq)Cool to room temperature (20-25 C)0.5 g of 20% palladium hydroxide on carbon (0.000712 mol, 0.015 eq)5 g of 2-cyanopyrimidine (0.0476 mol, 1.0 eq),Sealed,Nitrogen was substituted 3 times,Hydrogen replacement 3 times,Keep hydrogen pressure 2atm,After stirring at room temperature (20-25 C) for 16 hours,TLC confirmed no raw materials,Insoluble matter was removed by filtration,Liquid separation,The organic phase was washed once with 50 mL of saturated brine,Cooled to 0-5 ,Into the hydrogen chloride gas of about 15g,Stir for 8 hours,TLC confirmed the reaction was complete,All off the protective group.The crude product was filtered,30mL ethanol beating,Filtered, dried to give 5.3g hydrochloride,Yield 76.8%Purity 99.1%.

Reference： [1]Patent: CN106831601,2017,A .Location in patent: Paragraph 0014; 0016; 0018; 0020; 0022

27
[ 372118-67-7 ]
[ 330785-84-7 ]
avanafil [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 30℃; for 24h;	In a 1L three bottle,Add (39.28 g, 0.10 mol) (S)-4-(3-chloro-4-methoxybenzylamino)-5-carboxylic acid-2-(2-hydroxymethyl-1-pyrrolidinyl)pyrimidine (AFZJT-3),(21.84 g, 0.15 mol) <strong>[372118-67-7]2-aminomethylpyrimidine hydrochloride</strong>,(28.76 g, 0.15 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride,(20.26 g, 0.15 mol) 1-hydroxybenzotriazole, 0.8L N,N-dimethylformamide,(30.36g, 0.30mol) triethylamine, reacted at 30C for 24h,HPLC showed that the reaction was complete, adding 1.2L of water, extraction with dichloromethane,Wash it twice with about 5% aqueous sodium carbonate,Deionized water was washed once, dried over anhydrous sodium sulfate, suction filtered, and the desiccant removed.Concentrate the dichloromethane solvent under reduced pressureAdd ethyl acetate to beat,The filter was filtered and dried under reduced pressure at 50 C for 5 h.40.72 g of atorvapine crude was obtained with a yield of 84.13%.The crude product prepared in the example is 10g,Perform column chromatography and recrystallize twice with methanol,5.48 g of purified valvafil was obtained with a purification yield of 54.80%;

Reference： [1]Patent: CN104151299,2017,B .Location in patent: Paragraph 0039; 0040; 0041; 0042

28
[ 372118-67-7 ]
5,7-dibromo-1-isopropyl-3-methyl-1H-pyrazolo[4,3-b]pyridine [ No CAS ]
5-bromo-1-isopropyl-3-methyl-N-(pyrimidin-2-ylmethyl)-1H-pyrazolo[4,3-b]pyridin-7-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With cesium fluoride; In 1-methyl-pyrrolidin-2-one; at 100℃; for 16h;	To a solution of 334 5,7-dibromo-1-isopropyl-3-methyl-1H-pyrazolo[4,3-b]pyridine (500 mg, 1.5 mmol) in NMP (1.5 mL) was added 697 <strong>[372118-67-7]pyrimidin-2-ylmethanamine hydrochloride</strong> (437 mg, 3 mmol) and 133 CsF (684 mg, 4.50 mmol), the resulting mixture was heated at 100 C. for 16 hours. The mixture was cooled to 25 C., then 56 ethyl acetate(50 mL) and 99 H2O(30 mL) were added, the organic layer was washed with H2O (50 mL×3), brine (50 mL×2), then concentrated. The residue was purified by flash silica gel chromatography (ethyl acetate/petroleum ether gradient 0100%) to afford 698 5-bromo-1-isopropyl-3-methyl-N-(pyrimidin-2-ylmethyl)-1H-pyrazolo[4,3-b]pyridin-7-amine. To a solution of 698 5-bromo-1-isopropyl-3-methyl-N-(pyrimidin-2-ylmethyl)-1H-pyrazolo[4,3-b]pyridin-7-amine (100 mg, 0.28 mmol) in 28 DMF (1 mL) was added 624 3-ethoxy-4-(tributylstannyl)pyridazine (229 mg, 0.55 mmol), 646 CuI (5 mg, 0.028 mmol) and 424 Pd(PPh3)4 (32 mg, 0.028 mmol), the reaction mixture was degassed with N2 and heated at 100 C. for 16 hours. The mixture was cooled to 25 C. and filtered and the filter cake was washed with ethyl acetate (10 mL). The filtrate was concentrated. The residue was purified by flash silica gel chromatography (MeOH/dichloromethane gradient 05%) to give the crude. The crude was purified by preparative TLC (SiO2, dichloromethane: MeOH=20:1) to afford the 700 title compound. 1H NMR (CDCl3 400 MHz): delta8.96 (d, J=4.8 Hz, 1H), 8.83 (d, J=5.2 Hz, 2H), 8.16 (d, J=4.8 Hz, 1H), 7.34-7.32 (m, 2H), 6.53 (brs, 1H), 5.16-5.10 (m, 1H), 4.78-4.73 (m, 4H), 2.67 (s, 3H), 1.72 (d, J=6.8 Hz, 6H), 1.56 (t, J=7.2 Hz, 3H). LC-MS: tR=1.71 minutes (Method L), m/z=405 [M+H]+.

Reference： [1]Patent: US2019/194189,2019,A1 .Location in patent: Paragraph 0812-0813

29
[ 372118-67-7 ]
4-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]benzo[b]thiophene-7-carboxylic acid [ No CAS ]
4-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-(2-pyrimidinylmethyl)benzo[b]thiophene-7-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
47 mg		A dry vial was charged with 4-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl]benzo[b]thiophene-7-carboxylic acid (75 mg, 0.16 mmol), HATU (34 mg, 0.24 mmol), and HOBT (5 mg, 0.031 mmol), and the vial was purged with nitrogen gas. DMF (0.2 mL) was added followed by DIPEA (0.10 mL, 0.55 mmol), and the reaction mixture was stirred at room temperature for 5 minutes. 2-(Aminomethyl)pyrimidine hydrochloride was then added, and the reaction was stirred at room temperature for 2 hours. The reaction mixture was then diluted with ethyl acetate, washed (saturated aqueous NaHCO3, water, brine), and concentrated in vacuo. The residue was purified by silica gel chromatography using ethyl acetate as eluent to provide 47 mg (52 %) of the title Compound, a Compound of this invention, as a yellow film. LC/MS [M+1]: 568.9. 1H NMR (500 MHz, CDCl3( ^ ggd: 3.83-3.93 (m, 1H) 4.23-4.33 (m, 1H) 4.96-5.05 (m, 2H) 7.27-7.32 (m, 1H) 7.44-7.50 (m, 1H) 7.62-7.67 (m, 2H) 7.78-7.86 (m, 2H) 7.87-7.93 (m, 1H) 8.28 (d, J=5.83 Hz, 1H) 8.78 (d, J=4.89 Hz, 2H).19F NMR (471 MHz, CDCl3( ^ ggd: -113.67 to -113.32 (m, 3F) -79.40 (s, 1F).

Reference： [1]Patent: WO2020/18610,2020,A1 .Location in patent: Page/Page column 59

30
[ 372118-67-7 ]
[ 201230-82-2 ]
8-bromo-5-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]isoquinoline [ No CAS ]
5-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-(2-pyrimidinylmethyl)-8-isoquinolinecarboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
45%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; triethylamine; In toluene; at 80℃; under 760.051 Torr; for 6h;	A mixture of 8-bromo-5-[5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl]isoquinoline (180 mg, 0.35 mmol), <strong>[372118-67-7]2-aminomethylpyrimidine hydrochloride</strong> (154 mg, 1.41 mmol), [l,r-bis(diphenylphosphino)ferrocene]- dichloropalladium(II) (29 mg, 0.04 mmol) and triethylamine (0.49 mL, 3.5 mmol) in toluene (10 mL) was stirred at 80 C under one atmosphere of carbon monoxide for 6 hr. The reaction mixture was then filtered through a short pad of Celite, rinsed with ethyl acetate, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography using ethyl acetate/methanol as eluent to afford the title compound, a compound of this disclosure, as a yellow solid (88 mg, 45% yield, 0.16 mmol). 1H NMR (DMSO-d6): 9.83 (s, 1H), 9.46 (t, 1H), 8.86 (d, 2H), 8.71 (s, 2H), 8.17 (d, 1H), 7.92 (d, 1H), 7.90 (s, 1H), 7.88 (s, 1H), 7.47 (t, 1H), 4.78 (d, 2H), 4.62 (d, 1H), 4.58 (d, 1H).

Reference： [1]Patent: WO2020/55955,2020,A1 .Location in patent: Page/Page column 33

Same Skeleton Products

Related Products

Historical Records

Pharmaceutical Intermediates of
[ 372118-67-7 ]

Avanafil Intermediates

[ 20187-46-6 ]

Ethyl 4-amino-2-hydroxypyrimidine-5-carboxylate

[ 71-30-7 ]

6-Aminopyrimidin-2(1H)-one

[ 23356-96-9 ]

L-Prolinol

[ 330785-84-7 ]

(S)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidine-5-carboxylic acid

[ 87-13-8 ]

Diethyl 2-(ethoxymethylene)malonate

Related Functional Groups of
[ 372118-67-7 ]

Amines

[ 75985-45-4 ]

Pyrimidin-2-ylmethanamine

Similarity: 0.97

[ 138588-40-6 ]

2-Amidinopyrimidine hydrochloride

Similarity: 0.90

[ 1083246-53-0 ]

N-Methyl-1-(pyrimidin-2-yl)methanamine

Similarity: 0.90

[ 45695-56-5 ]

Pyrimidine-2-carboximidamide

Similarity: 0.88

[ 1616809-52-9 ]

1-(Pyrimidin-2-yl)ethanamine hydrochloride

Similarity: 0.82

Related Parent Nucleus of
[ 372118-67-7 ]

Pyrimidines

[ 75985-45-4 ]

Pyrimidin-2-ylmethanamine

Similarity: 0.97

[ 138588-40-6 ]

2-Amidinopyrimidine hydrochloride

Similarity: 0.90

[ 1083246-53-0 ]

N-Methyl-1-(pyrimidin-2-yl)methanamine

Similarity: 0.90

[ 45695-56-5 ]

Pyrimidine-2-carboximidamide

Similarity: 0.88

[ 1616809-52-9 ]

1-(Pyrimidin-2-yl)ethanamine hydrochloride

Similarity: 0.82

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 372118-67-7 ] {[proInfo.proName]}

Quality Control of [ 372118-67-7 ]

Related Doc. of [ 372118-67-7 ]

Product Details of [ 372118-67-7 ]

Calculated chemistry of [ 372118-67-7 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 372118-67-7 ]

Application In Synthesis of [ 372118-67-7 ]

[ 372118-67-7 ] Synthesis Path-Downstream 1~30

Pharmaceutical Intermediates of [ 372118-67-7 ]

Avanafil Intermediates

Related Functional Groups of [ 372118-67-7 ]

Amines

Related Parent Nucleus of [ 372118-67-7 ]

Pyrimidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Pharmaceutical Intermediates of
[ 372118-67-7 ]

Related Functional Groups of
[ 372118-67-7 ]

Related Parent Nucleus of
[ 372118-67-7 ]